How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Safety and Efficacy of Albuterol Administered by the Halixâ„¢ Dry Powder Inhaler in Subjects With Asthma

, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device, having one male sexual partner who has undergone vasectomy); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone

2018 Clinical Trials

102. National Adaptive Trial for PTSD Related Insomnia

be willing to use a reliable form of contraception for 16 weeks (during study treatment and for 2 weeks after taking the last dose) which includes: barrier contraceptives (male or female condoms with or without a spermicide, diaphragm or cervical cap with spermicide, or intrauterine device) and hormone-based therapy (contraceptive pills, intrauterine devices, or Depo-Provera�) Birth control for female participants is not necessary if surgically sterile or if with a partner with whom they are not capable

2018 Clinical Trials

103. India Dexamethasone and Betamethasone

alcoholic consumption during the study duration. - Absence of disease markers of HIV I and 2, Hepatitis Band C and Syphilis. - Female subjects of childbearing potential must be using two acceptable methods of contraception, ( e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, progestin only implants and long acting injectables (Depo Provera), etc.). These measures are required during the study and for at least two weeks after the last dose and conveyed

2018 Clinical Trials

104. Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

of contraception include oral contraceptives, barrier with spermicide, IUD, levonorgestrel implant (Norplant ®), medroxyprogesterone acetate (Depo Provera ®), surgical sterilization, contraceptive patch, vaginal contraceptive ring, and complete abstinence (not having sex)); able to provide at least 2 locators; able to provide voluntary informed consent. Exclusion Criteria: Current alcohol withdrawal (AW), evidenced by CIWA-Ar scale > 7 Severe psychiatric conditions, including past or current DSM-5 diagnosis

2018 Clinical Trials

105. A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

implants, progesterone releasing intrauterine devices [IUDs], vaginal ring, and postcoital contraceptive methods) and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of investigational product. Use of hormone based intravaginal creams (i.e., Estrace) for treatment of vaginal dryness, itching, or burning due to menopause and/or vulvovaginal atrophy Depo Provera must have been discontinued at least 6 months prior to the first dose of investigational

2018 Clinical Trials

106. Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

(excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (stabilized for at least 3 months

2018 Clinical Trials

107. Hormonal Contraceptive Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically

(DMPA) as contraception. Drug: Depot medroxyprogesterone acetate (DMPA) Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks Other Names: Medroxyprogesterone acetate (MPA) Depo-Provera Etonogestrel implant (Eng-Implant) This arm includes subjects that choose Etonogestrel implant (Eng-Implant

2018 Clinical Trials

108. Single Hormone Closed Loop Study With PDT Sensor

contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non

2018 Clinical Trials

109. Olaparib in People With Malignant Mesothelioma

Intrauterine Device PLUS male condom. Provided coils are copper-banded. Etonogestrel implants (e.g., Implanon , Norplant ) PLUS male condom Normal and low dose combined oral pills PLUS male condom Hormonal shot or injection (e.g., Depo-Provera) PLUS male condom Intrauterine system device (e.g., levonorgestrel-releasing intrauterine system -Mirena ) PLUS male condom Norelgestromin/ethinyl estradiol transdermal system PLUS male condom Intravaginal device (e.g., ethinyl estradiol and etonogestrel) PLUS male

2018 Clinical Trials

110. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner (shown successful as per appropriate follow-up) BMI of 18.5 kg/m²-32.5 kg/m² Agrees to comply with study procedures Willing to commit to taking product for 128 days

2018 Clinical Trials

111. An Intermediate Expanded Use Trial of DFMO

after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines Exclusion

2018 Clinical Trials

112. GABA Pathways in Autism Spectrum Disorder (ASD)

), medroxyprogesterone injections (e.g. Depo-Provera), etonogestrel implants (e.g., Implanon, Norplan), normal and low dose combined oral contraceptive pills, norelgestromin / EE transdermal system, intravaginal device (e.g., EE and etonogestrel) and desogestrel (Cerazette). Pregnancy or breastfeeding (is a routine exclusion for research MRI scanning). Female study participants must be willing to use one form of highly effective non-hormonal contraception for one week after study drug administration. This would

2018 Clinical Trials

113. A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous Administration of TV46046

(decompensated) or liver tumors has known significant renal disease has a history of diagnosed clinical depression or bipolar disorder, with or without suicidal ideation, and/or history of suicide attempt is currently using hormonal contraception had an injection of DMPA (Depo-Provera CI or Depo-subQ 104) in the past 12 months; or combined injectable in the last 3 months is chronically using pain medication has a plan to move to another location in the next 18 months Additional criteria apply, please contact (...) Administration of TV-46046 Actual Study Start Date : January 15, 2019 Estimated Primary Completion Date : June 17, 2020 Estimated Study Completion Date : June 17, 2020 Arms and Interventions Go to Arm Intervention/treatment Experimental: TV-46046 - 1 One of 24 sequences Drug: TV-46046 - 1 120 mg/0.3 mL Drug: TV-46046 - 2 60 mg/0.3 mL of 1:1 saline-diluted TV-46046 Drug: medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL (injectable suspension) Other Name: Depo-subQ 104 Drug: TV-46046 Placebo

2018 Clinical Trials

114. Daily Liraglutide for Nicotine Dependence

as "intend to quit within one month"). Body mass index (BMI) greater than or equal to 27 kg/m2 with one weight-related comorbidity (e.g. high blood pressure, high cholesterol, dyslipidemia) or greater than or equal to 30 kg/m2 per the manufacturer label for weight management. Women of childbearing potential (based on medical history) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, intrauterine

2018 Clinical Trials

115. Three Way Crossover Closed Loop Study With Xeris Glucagon

. Current use of a phone or other device so can be contacted by study staff off-campus. Willingness to follow all study procedures, including attending all clinic visits. Willingness to sign informed consent and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera, Norplant, an IUD

2018 Clinical Trials

116. Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

contraception (e.g., oral contraceptives of estrogen and progestin combinations); depot injection (e.g., Depo-Provera); contraceptive implant (e.g., Norplant, Implanon); transdermally delivered contraceptive (e.g., Ortho Evra); intrauterine device; vaginal contraceptive ring (e.g.,NuvaRing); diaphragm plus spermicide; cervical cap; or male condom plus spermicide; partner vasectomy at least 6 months prior to baseline Vision and hearing (hearing aid permissible) sufficient for compliance with testing

2018 Clinical Trials

117. Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

: Only participants who meet all the inclusion criteria will be enrolled into the trial; Group 1: Healthy male or female adults aged 18-35 years at the time of enrolment with signed consent. Group 1 (Female only participants): Must be non-pregnant (as demonstrated by a negative urine pregnancy test), and provide consent of their willingness to take Depo-Provera contraceptive during the study and safety follow-up period. Groups 2a & 2b: Healthy male or female young children aged 1-6 years at the time

2018 Clinical Trials

118. Evaluation of Physician-based Decision Support

of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure

2018 Clinical Trials

119. A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

-uterine devices (IUD), or using hormonal implants (e.g., Norplant) or injections (e.g., Depo-Provera) for contraception or used within the past 6 months; Patient is currently using an oral contraceptive for less than 3 months, has been on a unstable dose within the last 3 months or has switched from one oral contraceptive to another within the last 3 months or intends to do so in the course of the study; Patient has a history of chronic abuse of alcohol (regularly consumes 3 or more alcoholic drinks

2018 Clinical Trials

120. Knowledge and utilization of family planning methods among people living with HIV in Kathmandu, Nepal. (PubMed)

to all of the eligible participants.The mean ± SD age of the participants was 36.62 ± 7.58 years. Sixty five percent of the respondents' spouses were HIV positive. A majority of the respondents (72%) had heard of seven modern family planning methods. Considerably high number (72%) of the respondents or their spouses were using at least one of the method of family planning. The most common method was condom (83%) and the least common was IUCD (0.50%). The use of short acting (pills, depo-provera

Full Text available with Trip Pro

2018 BMC Health Services Research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>